Lung Cancer Stage IV Clinical Trial
Official title:
Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression. For multiple metastases in patients with advanced NSCLC, increased local treatment may benefit to prolong patient survival. This study investigated the benefits of icotinib limited systemic disease progression and continuation of Stereotactic Body Radiation Therapy,in patients with metastatic EGFR-mutant NSCLC.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | May 2, 2019 |
Est. primary completion date | November 2, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR mutation. - Stage disease according to the 7th Edition of the American Joint Committee on Cancer staging system - Not received radiotherapy, chemotherapy or other biological treatment - Measureable disease - Life expectancy of>=12 months - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 - Absolute neutrophil count (ANC)>=2,500/mm^3 - Hemoglobin>=9.0 g/dL - Total bilirubin<=1.5 x upper limit of normal(ULN) - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine transferase [ALT])<=2.5 x ULN in patients without liver or bone metastases; <5 x ULN in patients with liver or bone metastases - Cockcroft-Gault calculated creatinine clearance of>=45 ml/min or creatinine<=1.5 x ULN - Prothrombin time (PT)<=1.5 x ULN - Partial thromboplastin time (PTT)<=ULN - Negative pregnancy test done<=7 days prior to randomization, for women of childbearing potential only - Provide informed written consent - Willing to return to Sichuan cancer hospital for follow-up - Willing to provide tissue and blood samples for correlative research purposes Exclusion Criteria: - Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component - Known allergic to EGFR TKI any ingredients - Prior chemotherapy or treatment for metastatic non-small cell lung cancer - Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per MD discretion - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm - Other active malignancy<=3 years prior to randomization; - Ongoing or active infection, symptomatic congestive heart failure , cardiac arrhythmia, psychiatric illness/social situations, or any other medical condition that would limit compliance with study requirements - History of bleeding diathesis or coagulopathy - Inadequately controlled hypertension (systolic blood pressure of>150 mmHg or diastolic pressure>100 mmHg on anti-hypertensive medications) - Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury <=28 days or core biopsy <=7 days prior to randomization - Pregnancy or breast-feeding women - Other situation which researchers think that doesn't fit into the group |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sichuan Cancer Hospital and Research Institute |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression free survival | the time to disease to progression according the RESCIT | four weeks | |
Secondary | object responsible rate | the proportion the patients have receives the complete remission and partial remission | four weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03668496 -
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
|
Phase 3 | |
Active, not recruiting |
NCT03322072 -
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
|
N/A | |
Recruiting |
NCT05497973 -
Psychosocial eHealth in Advanced Lung Cancer
|
N/A | |
Recruiting |
NCT06076005 -
Lung Cancer ID (Identity) Study
|
||
Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05311709 -
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
|
Phase 2 | |
Completed |
NCT04825912 -
Resilience Measurement in Older Adults With Late-Stage Lung Cancer
|
N/A | |
Completed |
NCT03529851 -
Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients
|
N/A | |
Completed |
NCT03558165 -
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
|
||
Completed |
NCT03076164 -
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
|
Phase 1/Phase 2 | |
Recruiting |
NCT04595734 -
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
|
||
Recruiting |
NCT04519983 -
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
|
Phase 2 | |
Not yet recruiting |
NCT05701384 -
Lazertinib 160mg in EGFR T790M NSCLC
|
Phase 2 | |
Withdrawn |
NCT03409341 -
Personalizing Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT03728361 -
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06024941 -
Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04669223 -
Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion
|
N/A | |
Recruiting |
NCT05996263 -
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
|
||
Completed |
NCT04057196 -
Self-System Therapy for Older Adults With Lung Cancer
|
N/A | |
Recruiting |
NCT06000358 -
The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer
|
N/A |